Experts document about an adequate utilization of SYSADOAs in controversial clinical situations Jordi Monfort; Xavier Carné; Benjamín Abarca; Sergio Giménez; Montserrat Romera; Ingrid Möller; Marco Bibas; Marianna Vitaloni; Aina Batlle; Josep Vergés;

A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis Alberto Jiménez-Morales; Rafael Cáliz; Susana Aceituno; Miriam Prades; Carles Blanch;

Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price Mariángeles González Fernández; Elena Villamañán; Inmaculada Jiménez-Nácher; Francisco Moreno; Chamaida Plasencia; Francisco Gayá; Alicia Herrero; Alejandro Balsa;